EFIC-Grünenthal Grant: Improve the Understanding of Pain and its Therapy

Nov 19, 2012, 06:42 ET from Grunenthal GmbH

AACHEN, Germany and BRUSSELS, November 19, 2012 /PRNewswire/ --

- Last call for 2012 applications at  http://www.e-g-g.info

Unique funding opportunity for young scientists from across Europe! Young researchers are invited to contribute with innovative research ideas and to apply for the EFIC-Grünenthal Grant (E-G-G) 2012, one of the most highly regarded grants worldwide in the field of pain research. Provided by the European Federation of IASP® Chapters (EFIC®) and the pharmaceutical company and pain expert Grünenthal, this grant gives young talented scientists the opportunity to translate their excellent ideas into clinical research projects. Scientists can submit their research projects online at http://www.e-g-g.info until the end of 2012.

Grünenthal donates a total of € 200,000 for the biennial grant, which is shared between the awarded scientists and is intended to support them early in their career. The individual grants are valued at up to € 40,000 per project for a duration of up to two years. The decision of the awards is made independently by the EFIC® Committee on Research.

The EFIC Grünenthal Grant aims at finding and supporting young pain researchers whose work will define how we understand and treat pain in the future. Learn more about the EFIC-Grünenthal Grant on the E-G-G Youtube Channel.

Guidelines, Quality Criteria and online application forms can be found at
http://www.e-g-g.info. Interested young scientists can submit their research projects online by December 31st 2012.

About EFIC®

The European Federation of IASP® Chapters (EFIC®) is a multidisciplinary professional organisation in the field of pain research and medicine, consisting of the 36 European chapters of the International Association of the Study of Pain (IASP®), which are the IASP®  accredited official pain societies in each country. Established in 1993, EFIC's constituent chapters represent pain societies from 36 European countries and close to 20,000 scientists, physicians, nurses, physiotherapists, psychologists and other healthcare professionals across Europe, who are involved in pain management and pain research. More about EFIC: http://www.efic.org.

About Grünenthal

The Grünenthal Group is an independent, family-owned international research based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain, its objective is to become the most patient-centric company to be a leader in therapy innovation. Grünenthal is one of the last five research-oriented pharmaceutical corporations with headquarters based in Germany which sustainably invests in research and development. These investments amounted to about 25 % of revenues in 2011. Grünenthal's research and development strategy concentrates on select fields of therapy and state-of-the-art technologies. We focus on the intensive search for new ways to treat pain better, more effectively and with fewer side-effects than before. Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries and approx. 4,500 employees are working for the Grünenthal Group worldwide. In 2011, Grünenthal reached estimated revenues of 947 Mio €. More information: http://www.grunenthal.com.

Grünenthal Contact: Frank Schönrock, Vice President Corporate Communications
Phone: +49-241-569-2161, Fax: +49-241-569-3539, frank.schoenrock@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany, http://www.grunenthal.com

EFIC® Contact: Christel Geevels, EFIC Executive Secretary
Phone: +32(2)251-55-10, Fax: +32(2)251-48-10, christel.geevels@efic.org
EFIC®, Grensstraat 7 - mailbox 3, 1831 Diegem, Belgium, http://www.efic.org.

SOURCE Grunenthal GmbH